© Reuters. AstraZeneca: data encouraging for Lynparza
AstraZeneca (LON:AZN) and Merck (NYSE:MRK) revealed encouraging data regarding their Lynparza in metastatic breast cancer, on the occasion of the annual meeting of the American Association for Cancer Research (AACR) in Chicago.
The two pharmaceutical groups report that in a phase III trial, their drug has achieved its primary goal of progression-free survival, with a median of 19.3 months compared to 17.1 months for patients treated with chemotherapy.
Copyright (c) 2018 CercleFinance.com. All rights reserved.